An updated meta-analysis of 23 case-control studies on the association between miR-34b/c polymorphism and cancer risk

Hua Li; Shuling Diao; Jingsen Li; Baoxin Ma; Shuanghu Yuan

doi:10.18632/oncotarget.16322

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

An updated meta-analysis of 23 case-control studies on the association between miR-34b/c polymorphism and cancer risk

Hua Li, Shuling Diao, Jingsen Li, Baoxin Ma _ and Shuanghu Yuan

PDF | HTML | How to cite

Oncotarget. 2017; 8:28888-28896. https://doi.org/10.18632/oncotarget.16322

Metrics: PDF 1628 views | HTML 2194 views | ?

Abstract

Hua Li1,*, Shuling Diao2,*, Jingsen Li2, Baoxin Ma2, Shuanghu Yuan3

1Department of Oncology, The Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256603, China

2Department of Cardiology, The Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256603, China

3Department of Radiotherapy, Shandong Cancer Hospital and Institute, Jinan, Shandong 250117, China

*These authors have contributed equally to this work

Correspondence to:

Baoxin Ma, email: [email protected]

Keywords: rs4938723, polymorphism, cancer risk, systematic review, meta-analysis

Received: October 15, 2016 Accepted: February 27, 2017 Published: March 17, 2017

ABSTRACT

The association between in microRNA-34b/c gene rs4938723 polymorphisms and cancer risk remains inconclusive. This meta-analysis was performed to analyze the association between microRNA-34b/c rs4938723 polymorphism and risk for cancer development. In total, 304 studies from PubMed, Embase, Web of Science, Wanfang, and Chinese National Knowledge Infrastructure databases were examined, and 23 studies were included in this meta-analysis. The 23 selected studies involved 10,812 cancer cases and 11,719 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to measure the strength of the association. Our results indicate a significant association between the rs4938723 polymorphism and cancer risk in the overdominant model (P heterogeneity = 0.018, OR = 1.093, and 95% CI = 1.015–1.177 for CT vs. CC/TT). Using a stratified subgroup analysis, rs4938723 polymorphisms were associated with an increased risk for hepatocellular carcinoma, but decreased risk for colorectal, gastric, and esophageal squamous cell cancer. These findings indicate that the rs4938723 gene is a susceptible locus for cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16322

Publication Alerts

Research Papers:

An updated meta-analysis of 23 case-control studies on the association between miR-34b/c polymorphism and cancer risk

Abstract